Seagen/Genmab's Tivdak Set To Take On Merck’s Keytruda
Executive Summary
Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.
You may also be interested in...
Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
Failure For AZ’s Imfinzi In CALLA Strengthens Keytruda’s Cervical Cancer Hold
An unexpected miss for AstraZeneca’s checkpoint inhibitor Imfinzi in cervical cancer, in the wake of other rivals dropping out, leaves Merck & Co’s Keytruda more firmly in command of the market.
Keytruda Cements Cervical Cancer Leadership With First-Line Nod
Although the label’s PD-L1 expression requirement could limit the addressable market, there is also potential for future combination with Seagen’s recently approved Tivdak.